tiprankstipranks
Nuvalent (NUVL)
NASDAQ:NUVL
US Market
Want to see NUVL full AI Analyst Report?

Nuvalent (NUVL) Stock Forecast & Price Target

181 Followers
See the Price Targets and Ratings of:

NUVL Analyst Ratings

Strong Buy
14Ratings
Strong Buy
14 Buy
0 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Nuvalent
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NUVL Stock 12 Month Forecast

Average Price Target

$141.54
▲(31.53% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Nuvalent in the last 3 months. The average price target is $141.54 with a high forecast of $164.00 and a low forecast of $116.00. The average price target represents a 31.53% change from the last price of $107.61.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"67":"$67","116":"$116","165":"$165","91.5":"$91.5","140.5":"$140.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":164,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$164.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":141.53846153846155,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$141.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":116,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$116.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[67,91.5,116,140.5,165],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,105.64,110.12923076923077,114.61846153846153,119.1076923076923,123.59692307692308,128.08615384615385,132.57538461538462,137.0646153846154,141.55384615384617,146.0430769230769,150.53230769230768,155.02153846153846,159.51076923076923,{"y":164,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,105.64,108.4014201183432,111.16284023668639,113.92426035502959,116.68568047337278,119.44710059171598,122.20852071005918,124.96994082840237,127.73136094674557,130.49278106508876,133.25420118343197,136.01562130177516,138.77704142011834,{"y":141.53846153846155,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,105.64,106.43692307692308,107.23384615384616,108.03076923076924,108.8276923076923,109.62461538461538,110.42153846153846,111.21846153846154,112.01538461538462,112.8123076923077,113.60923076923076,114.40615384615384,115.20307692307692,{"y":116,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.23,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.18,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.76,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.58,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.59,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.95,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.29,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.64,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$164.00Average Price Target$141.54Lowest Price Target$116.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on NUVL
Canaccord Genuity
Canaccord Genuity
$126
Buy
17.09%
Upside
Reiterated
04/30/26
Canaccord Genuity Sticks to Their Buy Rating for Nuvalent (NUVL)
Stifel Nicolaus Analyst forecast on NUVL
Stifel Nicolaus
Stifel Nicolaus
$135
Buy
25.45%
Upside
Reiterated
04/27/26
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Nuvalent (NASDAQ: NUVL)
H.C. Wainwright Analyst forecast on NUVL
H.C. Wainwright
H.C. Wainwright
$155
Buy
44.04%
Upside
Reiterated
04/21/26
Nuvalent Buy Rating: Zidesamtinib’s Differentiated ROS1 CNS Efficacy Supports $155 Target Price
TD Cowen Analyst forecast on NUVL
TD Cowen
TD Cowen
Buy
Reiterated
04/20/26
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS) and Nuvalent (NASDAQ: NUVL)
Wedbush
$125
Buy
16.16%
Upside
Reiterated
04/08/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Nuvalent (NASDAQ: NUVL) and Innoviva (NASDAQ: INVA)
LifeSci Capital Analyst forecast on NUVL
LifeSci Capital
LifeSci Capital
$142
Buy
31.96%
Upside
Reiterated
04/07/26
Nuvalent: Buy Rating on Strong Pipeline Execution, Dual NDA Momentum, and Solid Cash Runway in Targeted NSCLC
Truist Financial Analyst forecast on NUVL
Truist Financial
Truist Financial
$105.43$140
Buy
30.10%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Privia Health Group (NASDAQ: PRVA), Nuvalent (NASDAQ: NUVL) and Tonix Pharma (NASDAQ: TNXP)
Wells Fargo
$116
Buy
7.80%
Upside
Assigned
04/02/26
Nuvalent initiated with an Overweight at Wells FargoNuvalent initiated with an Overweight at Wells Fargo
J.P. Morgan Analyst forecast on NUVL
J.P. Morgan
J.P. Morgan
$145$152
Buy
41.25%
Upside
Reiterated
03/13/26
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP)
UBS
$132$138
Buy
28.24%
Upside
Reiterated
03/02/26
Nuvalent price target raised to $138 from $132 at UBSNuvalent price target raised to $138 from $132 at UBS
Jefferies Analyst forecast on NUVL
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$164
Buy
52.40%
Upside
Reiterated
02/27/26
Jefferies Sticks to Their Buy Rating for Nuvalent (NUVL)
Cantor Fitzgerald Analyst forecast on NUVL
Cantor Fitzgerald
Cantor Fitzgerald
$135$140
Buy
30.10%
Upside
Reiterated
02/27/26
Cantor Fitzgerald Remains a Buy on Nuvalent (NUVL)
Barclays Analyst forecast on NUVL
Barclays
Barclays
$152
Buy
41.25%
Upside
Reiterated
02/26/26
Barclays Sticks to Their Buy Rating for Nuvalent (NUVL)
Guggenheim Analyst forecast on NUVL
Guggenheim
Guggenheim
$155
Buy
44.04%
Upside
Reiterated
02/26/26
Guggenheim Remains a Buy on Nuvalent (NUVL)
Raymond James Analyst forecast on NUVL
Raymond James
Raymond James
$98.59$133
Buy
23.59%
Upside
Reiterated
01/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Disc Medicine (NASDAQ: IRON), Nuvalent (NASDAQ: NUVL) and Roche Holding AG (Other OTC: RHHVF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on NUVL
Canaccord Genuity
Canaccord Genuity
$126
Buy
17.09%
Upside
Reiterated
04/30/26
Canaccord Genuity Sticks to Their Buy Rating for Nuvalent (NUVL)
Stifel Nicolaus Analyst forecast on NUVL
Stifel Nicolaus
Stifel Nicolaus
$135
Buy
25.45%
Upside
Reiterated
04/27/26
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Nuvalent (NASDAQ: NUVL)
H.C. Wainwright Analyst forecast on NUVL
H.C. Wainwright
H.C. Wainwright
$155
Buy
44.04%
Upside
Reiterated
04/21/26
Nuvalent Buy Rating: Zidesamtinib’s Differentiated ROS1 CNS Efficacy Supports $155 Target Price
TD Cowen Analyst forecast on NUVL
TD Cowen
TD Cowen
Buy
Reiterated
04/20/26
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS) and Nuvalent (NASDAQ: NUVL)
Wedbush
$125
Buy
16.16%
Upside
Reiterated
04/08/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Nuvalent (NASDAQ: NUVL) and Innoviva (NASDAQ: INVA)
LifeSci Capital Analyst forecast on NUVL
LifeSci Capital
LifeSci Capital
$142
Buy
31.96%
Upside
Reiterated
04/07/26
Nuvalent: Buy Rating on Strong Pipeline Execution, Dual NDA Momentum, and Solid Cash Runway in Targeted NSCLC
Truist Financial Analyst forecast on NUVL
Truist Financial
Truist Financial
$105.43$140
Buy
30.10%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Privia Health Group (NASDAQ: PRVA), Nuvalent (NASDAQ: NUVL) and Tonix Pharma (NASDAQ: TNXP)
Wells Fargo
$116
Buy
7.80%
Upside
Assigned
04/02/26
Nuvalent initiated with an Overweight at Wells FargoNuvalent initiated with an Overweight at Wells Fargo
J.P. Morgan Analyst forecast on NUVL
J.P. Morgan
J.P. Morgan
$145$152
Buy
41.25%
Upside
Reiterated
03/13/26
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP)
UBS
$132$138
Buy
28.24%
Upside
Reiterated
03/02/26
Nuvalent price target raised to $138 from $132 at UBSNuvalent price target raised to $138 from $132 at UBS
Jefferies Analyst forecast on NUVL
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$164
Buy
52.40%
Upside
Reiterated
02/27/26
Jefferies Sticks to Their Buy Rating for Nuvalent (NUVL)
Cantor Fitzgerald Analyst forecast on NUVL
Cantor Fitzgerald
Cantor Fitzgerald
$135$140
Buy
30.10%
Upside
Reiterated
02/27/26
Cantor Fitzgerald Remains a Buy on Nuvalent (NUVL)
Barclays Analyst forecast on NUVL
Barclays
Barclays
$152
Buy
41.25%
Upside
Reiterated
02/26/26
Barclays Sticks to Their Buy Rating for Nuvalent (NUVL)
Guggenheim Analyst forecast on NUVL
Guggenheim
Guggenheim
$155
Buy
44.04%
Upside
Reiterated
02/26/26
Guggenheim Remains a Buy on Nuvalent (NUVL)
Raymond James Analyst forecast on NUVL
Raymond James
Raymond James
$98.59$133
Buy
23.59%
Upside
Reiterated
01/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Disc Medicine (NASDAQ: IRON), Nuvalent (NASDAQ: NUVL) and Roche Holding AG (Other OTC: RHHVF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nuvalent

3 Months
xxx
Success Rate
11/17 ratings generated profit
65%
Average Return
+6.45%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +6.45% per trade.
1 Year
Andrew BerensLeerink Partners
Success Rate
8/11 ratings generated profit
73%
Average Return
+12.85%
Copying Andrew Berens's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +12.85% per trade.
2 Years
xxx
Success Rate
10/11 ratings generated profit
91%
Average Return
+29.40%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +29.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NUVL Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
3
3
4
4
3
Buy
28
23
19
21
24
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
31
26
23
25
27
In the current month, NUVL has received 27 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NUVL average Analyst price target in the past 3 months is 141.54.
Each month's total comprises the sum of three months' worth of ratings.

NUVL Financial Forecast

NUVL Earnings Forecast

Next quarter’s earnings estimate for NUVL is -$1.34 with a range of -$1.60 to -$1.20. The previous quarter’s EPS was -$1.58. NUVL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NUVL has Performed in-line its overall industry.
Next quarter’s earnings estimate for NUVL is -$1.34 with a range of -$1.60 to -$1.20. The previous quarter’s EPS was -$1.58. NUVL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NUVL has Performed in-line its overall industry.
No data currently available

NUVL Sales Forecast

Next quarter’s sales forecast for NUVL is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. NUVL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NUVL has Performed in-line its overall industry.
Next quarter’s sales forecast for NUVL is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. NUVL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NUVL has Performed in-line its overall industry.

NUVL Stock Forecast FAQ

What is NUVL’s average 12-month price target, according to analysts?
Based on analyst ratings, Nuvalent’s 12-month average price target is 141.54.
    What is NUVL’s upside potential, based on the analysts’ average price target?
    Nuvalent has 31.53% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NUVL a Buy, Sell or Hold?
          Nuvalent has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Nuvalent’s price target?
            The average price target for Nuvalent is 141.54. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $164.00 ,the lowest forecast is $116.00. The average price target represents 31.53% Increase from the current price of $107.61.
              What do analysts say about Nuvalent?
              Nuvalent’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of NUVL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.